Medically Trained Senior Executive/Board
Member with Extensive Experience in Clinical Research and Drug
Development
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX),
a clinical-stage biotechnology company developing novel cell
transplants for serious medical conditions, today announced the
appointment of Dr. Dipti Amin, MBBS, FFPM, MRCGP, DCPSA, DCH,
DRCOG, DGM, to the Company’s Board of Directors, effective as of
April 20, 2021. Dr. Amin is an experienced Non-Executive Director
and a medically trained senior executive with broad expertise in
medicine, pharmacology, healthcare, research, and product
development. Dr. Amin has more than 26 years of experience within
the pharmaceutical sector and is accomplished across diverse
functional areas including clinical research, drug development,
ethics and compliance, and commercial operations. She currently
serves as a Non-Executive Director on the board of directors of
Buckinghamshire Healthcare National Health Service Trust and the
University of Hertfordshire in the UK.
“We are honored that Dr. Amin will be joining Lineage’s Board of
Directors at this important time in the advancement of our mission
to become the leading allogeneic cell transplant company,” stated
Al Kingsley, Lineage’s Chairman of the Board. “Dr. Amin has had
leadership responsibility for many aspects of pharmaceutical
product development and clinical trials and has worked with
numerous sponsors on countless product candidates while at
Quintiles (now IQVIA). We believe her breadth of experience in
clinical research and drug development, as well as her medical
expertise and practical operational experience, will be
particularly valuable to our Board and management team as Lineage
continues to advance its three product candidates toward later
stage clinical trials. We look forward to her support in guiding
our corporate, product, and clinical strategy as we position
ourselves for years of growth in the field of cell therapy.”
“Lineage’s clinical-stage programs and platform technologies
have the potential to transform outcomes for patients suffering
from serious medical conditions,” stated Dr. Amin. “I am excited
about the opportunity to contribute to the Company’s future growth.
I particularly look forward to helping guide the advancement of
Lineage’s novel cell therapy product candidates toward later-stage
clinical trials and the execution of other potentially valuable
development activities, with an ultimate focus on transforming the
lives of patients and creating value for the Company’s
shareholders.”
Dipti Amin, MBBS, FFPM, MRCGP, DCPSA,
DCH, DRCOG, DGM
Dipti Amin is an experienced Non-Executive Director and
medically trained senior executive with a passion for high quality
pharmaceutical research and healthcare, and extensive commercial,
leadership, operational experience, in the private & public
sectors, in medicine, pharmacology and the highly-regulated
healthcare & research sectors, as well as compliance expertise.
Over a span of more than 26 years, Dr. Amin has held positions of
operational and strategic responsibility within Pharmaceutical
Services at the C-suite and Board level, delivering consistently on
growth, quality, customer, employee and process targets. Her broad
experience covers Clinical Pharmacology, ethical issues in clinical
research, drug development, ethics and compliance programs as well
as leadership and management of large, multi-functional,
multi-geography, global groups to deliver value-added, efficient
growth and achieving business turnarounds. Dr. Amin has extensive
international operational experience, including in the U.S., India,
East Asia and Africa.
Dr. Amin spent more than 20 years at Quintiles Transnational
(now IQVIA), the world’s largest provider of biopharmaceutical
development & commercial outsourcing services. During her
tenure, Dr. Amin served in a number of senior executive roles
including: Compliance; Ethics & Quality; Drug Safety and
Medical Affairs; Medical and Scientific Services; Regulatory
Affairs, Medical Writing and Strategic Drug Development; and
Clinical Development and Scientific Operations. Dr. Amin has
successfully developed strategy and helped grow the P&L, sales
& management for business units generating up to $600 million
in revenue, while employing internationally based, multi-functional
groups of highly qualified personnel. Dr. Amin is an Honorary
Lecturer in Clinical Pharmacology at Guy’s, King’s, and St. Thomas’
Hospitals Medical & Dental Schools. Dr. Amin has also served on
the Boards of Cambridge Innovation Capital and the Faculty of
Pharmaceutical Medicine of the Royal College of Physicians, on the
Innovation Board and Medical Expert Network of the Association of
the British Pharmaceutical Industry, on a Department of Health
Multi-centre Research Ethics Committee, on the Emerging Science and
Bioethics Advisory Committee of the Dept. of Health, and on the
Board of Governors of Heathfield School for Girls (The Girls’ Day
School Trust).
Dr. Amin received her MB, BS (Bachelor of Medicine; Bachelor of
Surgery) from Guys Hospital and St Thomas’ Hospitals (now GKT)
Medical School in 1987. She holds the following certifications:
DRCOG (Diploma of the Royal College of Obstetrics &
Gynaecologists), DGM (Diploma in Geriatric Medicine of the Royal
College of Physicians), MRCGP (Member of the Royal College of
General Practitioners), DCH (Diploma in Child Health of the Royal
College of Physicians), DCPSA (Diploma in Clinical Pharmacology),
MFPM (Awarded Membership by Distinction of the Faculty of
Pharmaceutical Medicine) and FFPM (Fellow of the Faculty of
Pharmaceutical Medicine). Her clinical research work has been
widely published in professional journals and textbooks, and she is
a recognized presenter at international conferences.
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics is a clinical-stage biotechnology
company developing novel cell therapies for unmet medical needs.
Lineage’s programs are based on its robust proprietary cell-based
therapy platform and associated in-house development and
manufacturing capabilities. With this platform Lineage develops and
manufactures specialized, terminally differentiated human cells
from its pluripotent and progenitor cell starting materials. These
differentiated cells are developed to either replace or support
cells that are dysfunctional or absent due to degenerative disease
or traumatic injury or administered as a means of helping the body
mount an effective immune response to cancer. Lineage’s clinical
programs are in markets with billion dollar opportunities and
include three allogeneic (“off-the-shelf”) product candidates: (i)
OpRegen®, a retinal pigment epithelium transplant therapy in Phase
1/2a development for the treatment of dry age-related macular
degeneration, a leading cause of blindness in the developed world;
(ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a
development for the treatment of acute spinal cord injuries; and
(iii) VAC, an allogeneic dendritic cell therapy platform for
immuno-oncology and infectious disease, currently in clinical
development for the treatment of non-small cell lung cancer. For
more information, please visit www.lineagecell.com or follow the
Company on Twitter @LineageCell.
Forward-Looking Statements
Lineage cautions you that all statements, other than statements
of historical facts, contained in this press release, are
forward-looking statements. Forward-looking statements, in some
cases, can be identified by terms such as “believe,” “may,” “will,”
“estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,”
“could,” “plan,” “potential,” “predict,” “seek,” “should,” “would,”
“contemplate,” project,” “target,” “tend to,” or the negative
version of these words and similar expressions. Such statements
include, but are not limited to, statements relating to Lineage’s
clinical advancement of its three product candidates, Lineage’s
potential growth in the field of cell therapy, the potential of
Lineage’s clinical-stage programs and platform technologies to help
patients, and Lineage’s positioning for future success.
Forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause Lineage’s actual
results, performance or achievements to be materially different
from future results, performance or achievements expressed or
implied by the forward-looking statements in this press release,
including risks and uncertainties inherent in Lineage’s business
and other risks described in Lineage’s filings with the Securities
and Exchange Commission (SEC). Lineage’s forward-looking statements
are based upon its current expectations and involve assumptions
that may never materialize or may prove to be incorrect. All
forward-looking statements are expressly qualified in their
entirety by these cautionary statements. Further information
regarding these and other risks is included under the heading “Risk
Factors” in Lineage’s periodic reports with the SEC, including
Lineage’s most recent Annual Report on Form 10-K filed with the SEC
and its other reports, which are available from the SEC’s website.
You are cautioned not to place undue reliance on forward-looking
statements, which speak only as of the date on which they were
made. Lineage undertakes no obligation to update such statements to
reflect events that occur or circumstances that exist after the
date on which they were made, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210422005259/en/
Lineage Cell Therapeutics, Inc. IR Ioana C. Hone
(ir@lineagecell.com) (442) 287-8963
Solebury Trout IR Gitanjali Jain Ogawa
(Gogawa@soleburytrout.com) (646) 378-2949
Russo Partners – Media Relations Nic Johnson or David
Schull Nic.johnson@russopartnersllc.com
David.schull@russopartnersllc.com (212) 845-4242
Lineage Cell Therapeutics (AMEX:LCTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Lineage Cell Therapeutics (AMEX:LCTX)
Historical Stock Chart
From Apr 2023 to Apr 2024